The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs.

Hepatology, medicine and policy Pub Date : 2016-10-18 eCollection Date: 2016-01-01 DOI:10.1186/s41124-016-0021-9
Eberhard Schatz, Katrin Schiffer, Mags Maher, Magdalena Harris, Xavier Major Roca, Mojca Maticic, Astrid Leicht
{"title":"The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs.","authors":"Eberhard Schatz,&nbsp;Katrin Schiffer,&nbsp;Mags Maher,&nbsp;Magdalena Harris,&nbsp;Xavier Major Roca,&nbsp;Mojca Maticic,&nbsp;Astrid Leicht","doi":"10.1186/s41124-016-0021-9","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment of hepatitis C has entered a new era since the advent of curative pharmaceuticals. As policy, government and civil society assemble in response, there are still gaps to be addressed. The Manifesto on Hepatitis C and Drug Use, launched in Berlin during the Correlation Hepatitis C Initiative conference in October 2014, was formulated and endorsed by many key organizations in the hepatitis field. The Manifesto takes strides to pinpoint shortcomings in hepatitis action oriented towards the population most affected by the hepatitis C virus (HCV): active drug users. Despite a considerable amount of evidence that active drug users are disproportionately affected by HCV, barriers to care remain. Engagement with representatives of communities of people who inject drugs (PWID) is imperative in order to effectively create guidelines which reflect reality. Unfortunately, widespread systemic stigmatization and lack of trust between affected communities, decision-makers and healthcare professionals have reproduced this divide. The Berlin Manifesto has identified a disconnect between evidence and action which must be answered. In this roundtable discussion, experts from diverse parts of the hepatitis community have contributed their perspectives and experience on access to prevention, testing, and treatment for HCV in PWID. The authors discuss relevant topics such as realities of access to HCV treatment in the United Kingdom, interventions of a regional network of active drug users in Europe and lack of PWID involvement in government policy in Catalonia. Collectively they challenge the neglect of HCV in PWID by many decision-makers and health care professionals and promote a scale-up of integrated prevention and treatment strategies focusing on this population. The authors' conclusions aim to clarify the discourse on hepatitis in order to prevent disease, save lives and work towards eventual hepatitis elimination.</p>","PeriodicalId":91692,"journal":{"name":"Hepatology, medicine and policy","volume":"1 ","pages":"14"},"PeriodicalIF":0.0000,"publicationDate":"2016-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s41124-016-0021-9","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology, medicine and policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41124-016-0021-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

The treatment of hepatitis C has entered a new era since the advent of curative pharmaceuticals. As policy, government and civil society assemble in response, there are still gaps to be addressed. The Manifesto on Hepatitis C and Drug Use, launched in Berlin during the Correlation Hepatitis C Initiative conference in October 2014, was formulated and endorsed by many key organizations in the hepatitis field. The Manifesto takes strides to pinpoint shortcomings in hepatitis action oriented towards the population most affected by the hepatitis C virus (HCV): active drug users. Despite a considerable amount of evidence that active drug users are disproportionately affected by HCV, barriers to care remain. Engagement with representatives of communities of people who inject drugs (PWID) is imperative in order to effectively create guidelines which reflect reality. Unfortunately, widespread systemic stigmatization and lack of trust between affected communities, decision-makers and healthcare professionals have reproduced this divide. The Berlin Manifesto has identified a disconnect between evidence and action which must be answered. In this roundtable discussion, experts from diverse parts of the hepatitis community have contributed their perspectives and experience on access to prevention, testing, and treatment for HCV in PWID. The authors discuss relevant topics such as realities of access to HCV treatment in the United Kingdom, interventions of a regional network of active drug users in Europe and lack of PWID involvement in government policy in Catalonia. Collectively they challenge the neglect of HCV in PWID by many decision-makers and health care professionals and promote a scale-up of integrated prevention and treatment strategies focusing on this population. The authors' conclusions aim to clarify the discourse on hepatitis in order to prevent disease, save lives and work towards eventual hepatitis elimination.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
《柏林丙型肝炎宣言》:为吸毒者提供预防、检测、治疗和护理。
自治疗药物问世以来,丙型肝炎的治疗进入了一个新的时代。在政策、政府和民间社会共同应对的同时,仍有差距有待解决。2014年10月,在柏林举行的“相关丙型肝炎倡议”会议期间,丙型肝炎和药物使用宣言在肝炎领域得到了许多重要组织的制定和认可。《宣言》在针对受丙型肝炎病毒影响最严重的人群(活跃吸毒者)的肝炎行动方面取得了重大进展,指出了这些行动的不足之处。尽管有相当多的证据表明,活跃吸毒者受到丙型肝炎病毒的影响不成比例,但获得治疗的障碍仍然存在。为了有效地制定反映现实的指导方针,必须与注射吸毒者社区的代表接触。不幸的是,受影响社区、决策者和卫生保健专业人员之间普遍存在的系统性污名化和缺乏信任使这种分歧再次出现。《柏林宣言》指出了证据与行动之间的脱节,这一问题必须得到解决。在这次圆桌讨论中,来自肝炎社区不同部门的专家就PWID中HCV预防、检测和治疗的可及性发表了他们的观点和经验。作者讨论了相关的主题,如在英国获得HCV治疗的现实,欧洲活跃吸毒者区域网络的干预措施,以及PWID在加泰罗尼亚政府政策中的缺乏参与。它们共同挑战了许多决策者和卫生保健专业人员对PWID中丙型肝炎病毒的忽视,并促进了以这一人群为重点的综合预防和治疗战略的扩大。作者的结论旨在澄清关于肝炎的论述,以便预防疾病、拯救生命并朝着最终消除肝炎的方向努力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Correlates of hepatitis B awareness and disease-specific knowledge among pregnant women in Northern and Central Uganda: a cross-sectional study. Correction to: Hepatology, Medicine and Policy: Articles with DOIs 10.1186/s41124-016-0014-8, 10.1186/s41124-016-0013-9 and 10.1186/s41124-016-0012-x. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Erratum: Publisher Correction to Hepatology, Medicine and Policy: Articles with DOIs 10.1186/s41124-017-0024-1, 10.1186/s41124-017-0025-0, 10.1186/s41124-017-0026-z and 10.1186/s41124-017-0027-y. Seroprevalence of hepatitis B and C in Nepal: a systematic review (1973-2017).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1